Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRIENDSHIP-GC-02: Proximal vs total gastrectomy after sintilimab + SOX neoadjuvant therapy for advanced gastroesophageal junction cancer
ChiCTR2500108364Phase 2Not yet recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of sintilimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by China-Japan Friendship Hospital. Primary endpoint: 3-year disease-free survival rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500108364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108364.